CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$22.09
−0.32%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$1.42B
MomentumView details →
1D Return
−0.32%
YTD Return
+114.12%
RSI (14)
62.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
Market Cap
$1.42B
RSI (14)
62.5
MomentumView details →
1D Return
−0.32%
YTD Return
+114.12%
SummaryUpdated Jun 1, 2026
Cullinan Oncology, Inc. (NASDAQ:CGEM) is a biopharmaceutical company founded in 2016 and headquartered in Cambridge, Massachusetts. The company went public in January 2021 and focuses on developing targeted oncology and immuno-oncology therapies for cancer patients. As a clinical-stage biotechnology company, Cullinan operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental cancer treatments through various stages of clinical trials.
Similar companies
Latest newsMore news →
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced positive Phase 3 trial data for zipalertinib as a first-line treatment for certain lung cancer patients.23d agoCullinan Therapeutics reported a net loss of $53.7 million for Q2 2026, with cash and investments of $356.0 million as of June 30, 2026.31d ago